Apple’s tablet device, it seems, is now pharma’s best friend, too. But it’s not as simple as just rolling up to the physician’s office, flashing your iPad for five minutes and watching market share soar.
Court nixes payoffs to generic firms
August 31, 2012
4:00 am
An appeals court ruling says “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market” can be taken as “evidence of an unreasonable restraint of trade.”
Ad spend for medical/surgical journals declined by 16.5%, as patent expiries and regulatory delays stifled 2011’s comeback bid. Marc Iskowitz reports on the numbers for the first half of 2012
Sites like Novo Nordisk’s Cornerstones4Care are bringing full-spectrum segmentation to the task of bolstering adherence and being there for the patient